Psyence Biomedical LtdNASDAQ:PBMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.0450
- TODAY'S CHANGE (%)-0.0020 (-4.2553%)
- Bid / Lots0.0451/ 150
- Ask / Lots0.0472/ 12
- Open / Previous Close0.0470 / 0.0470
- Day Range
- 52 Week Range
- Volume7,069,711
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PBM |
|---|---|---|
| 09:32 ET | 60551 | 0.044 |
| 09:33 ET | 200 | 0.044899 |
| 09:35 ET | 14872 | 0.0447 |
| 09:37 ET | 143874 | 0.0439 |
| 09:39 ET | 92153 | 0.0431 |
| 09:42 ET | 26200 | 0.0433 |
| 09:44 ET | 8773 | 0.043156 |
| 09:46 ET | 51794 | 0.0431 |
| 09:48 ET | 94641 | 0.0431 |
| 09:50 ET | 208132 | 0.0432 |
| 09:51 ET | 6523 | 0.0439 |
| 09:53 ET | 12355 | 0.0438 |
| 09:55 ET | 26500 | 0.0436 |
| 09:57 ET | 13234 | 0.0438 |
| 10:02 ET | 200 | 0.0434 |
| 10:04 ET | 5600 | 0.0437 |
| 10:06 ET | 2688 | 0.0437 |
| 10:08 ET | 102256 | 0.044 |
| 10:11 ET | 17390 | 0.04411 |
| 10:13 ET | 300 | 0.044001 |
| 10:15 ET | 500 | 0.0446 |
| 10:18 ET | 27217 | 0.0445 |
| 10:20 ET | 26313 | 0.0449 |
| 10:22 ET | 136735 | 0.045 |
| 10:24 ET | 625 | 0.0446 |
| 10:26 ET | 206305 | 0.044 |
| 10:27 ET | 129457 | 0.0441 |
| 10:29 ET | 799 | 0.0441 |
| 10:31 ET | 400 | 0.0448 |
| 10:33 ET | 3740 | 0.045 |
| 10:36 ET | 386 | 0.045 |
| 10:38 ET | 1010 | 0.0447 |
| 10:40 ET | 300 | 0.0449 |
| 10:42 ET | 4400 | 0.0452 |
| 10:44 ET | 6075 | 0.0449 |
| 10:45 ET | 140154 | 0.0456 |
| 10:47 ET | 7044 | 0.0456 |
| 10:54 ET | 31100 | 0.0457 |
| 10:56 ET | 1062 | 0.04515 |
| 10:58 ET | 8339 | 0.0459 |
| 11:00 ET | 11551 | 0.0457 |
| 11:03 ET | 242666 | 0.047 |
| 11:05 ET | 115235 | 0.0471 |
| 11:07 ET | 2000 | 0.0457 |
| 11:09 ET | 3500 | 0.0473 |
| 11:12 ET | 208200 | 0.045 |
Nov 20, 2024
Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing, from 7:30AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:30AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 19, 2024
Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation, from 4:05PM ET on Tuesday Nov 19, 2024 by Dow Jones
4:05PM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 12, 2024
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq, from 4:30PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:30PM ET on Tuesday Nov 12, 2024 by Dow JonesPress Release: Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq, from 4:30PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:30PM ET on Tuesday Nov 12, 2024 by Dow Jones
Oct 31, 2024
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs, from 9:30AM ET on Thursday Oct 31, 2024 by Dow Jones
9:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Psyence Biomedical Ltd | 3.0M | -1.0x | --- |
Processa Pharmaceuticals Inc | 2.9M | -0.2x | --- |
Eastgate Biotech Corp | 3.2M | -0.9x | --- |
PainReform Ltd | 1.9M | 0.0x | --- |
CannaPharmaRx Inc | 2.0M | -0.8x | --- |
AgriFORCE Growing Systems Ltd | 4.8M | 0.0x | --- |
Company Information
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Contact Information
- Headquarters
- 121 Richmond Street West Penthouse Suite 1300TORONTO, ON, Canada M5H 2K1
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Michael Jordaan
- Chief Executive Officer, Director
- Marc Balkin
- Chief Financial Officer
- Jurgen van De Vyver
- Independent Director
- Simran Aggarwal
- Independent Director
- Rohit Bodas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 63.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.04 |
Book Value | $7.49 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 2.0x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
